Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
Background & Aims: TMC435 is an investigational, once-daily, oral NS3/4A protease inhibitor currently in phase III development for the treatment of hepatitis C virus (HCV) infection. Phase I and II studies in patients infected with HCV genotype 1 have demonstrated that TMC435 is generally well t...
Saved in:
Main Authors: | Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861188748&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51890 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
by: Christophe Moreno, et al.
Published: (2018) -
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
by: Moreno C., et al.
Published: (2017) -
LTI, Laguna-Calamba TMC microwave link design
by: Sabah, Nesser Moh'd
Published: (1998) -
Semi-continuous production of biodiesel from palm fatty acid using novozym 435
by: Sukanya Subkerd
Published: (2010) -
EXPLORING THE MOLECULAR BASIS OF DRUG RESISTANCE TO PA-824 AND TMC207
by: HANA LEI HAVER
Published: (2013)